Jung-young Shin
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
FOXA2 and STAT5A regulate oncogenic activity of KIF5B-RET fusion.
Journal: American journal of cancer research
Published: February 02, 2022
A Highly Sensitive Next-Generation Sequencing-Based Genotyping Platform for EGFR Mutations in Plasma from Non-Small Cell Lung Cancer Patients.
Journal: Cancers
Published: September 26, 2020
Detection of RET (rearranged during transfection) variants and their downstream signal molecules in RET rearranged lung adenocarcinoma patients.
Journal: Surgical oncology
Published: December 08, 2017
KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas.
KIF5B-RET Fusion gene may coincide oncogenic mutations of EGFR or KRAS gene in lung adenocarcinomas.
Journal: Diagnostic pathology
Published: April 15, 2015
Genetic Variations of Drug Transporters Can Influence on Drug Response in Patients Treated with Docetaxel Chemotherapy.
Journal: Cancer research and treatment
Published: January 09, 2014
A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
Journal: Cancer biology & therapy
Published: June 25, 2013
Molecular genetic characterization of p53 mutated oropharyngeal squamous cell carcinoma cells transformed with human papillomavirus E6 and E7 oncogenes.
Journal: International journal of oncology
Published: March 08, 2013
The transcriptional landscape and mutational profile of lung adenocarcinoma.
Journal: Genome research
Published: September 15, 2012
Showing 1-11 of 11
Last Updated: 09/26/2026